Investigators at the Mass General Hospital and affiliate institutions desire to continue their 20 year tradition of participation in all research activities of Cancer and Leukemia Group B (CALGB) in an effort to promote better understanding of, and treatment for, the neoplastic diseases in which CALGB is interested. A primary goal is to provide state-of-the-art treatment for patients with neoplastic diseases, while making a scientific contribution to definition of optimal management strategies and basic pathophysiologic understanding of these diseases. The collaborative investigators will maintain a local office for registration of cases on CALGB protocols, and will provide assistance to physicians and patients to facilitate patient protocol enrollment and data management assistance. This office will also maintain conformity with human studies protection requirements, arrange procurement of experimental drugs in conjunction with the MGH Pharmacy, and implement logistical measures to deal with the procurement of various specimens as per protocol requirements, and the mailing of these specimens to the designated laboratories. The local center will be equipped with an efficient computer- based electronic mail system, placing this unit of CALGB in close connection with all other such units as well as the central administration office and the data processing center. A complete registry of available CALGB protocols will be maintained; information about new studies and data updates will be disseminated on a regular basis to the associated investigators at a series of local meetings, at regular tumor board meetings, and by newsletters as information becomes available.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA012449-20
Application #
3556139
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1979-04-01
Project End
1993-03-31
Budget Start
1990-04-20
Budget End
1991-03-31
Support Year
20
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Ogino, Shuji; Liao, Xiaoyun; Imamura, Yu et al. (2013) Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst 105:1789-98
Lichtman, S M; Hurria, A; Cirrincione, C T et al. (2012) Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840. Ann Oncol 23:632-8
Garber, Judy E; Halabi, Susan; Tolaney, Sara M et al. (2010) Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. J Natl Cancer Inst 102:942-9
Smith, S M; Johnson, J; Cheson, B D et al. (2009) Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691. Leuk Lymphoma 50:1606-17
Grinblatt, David L; Yu, Daohai; Hars, Vera et al. (2009) Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803). Cancer 115:84-93
Stinchcombe, Thomas E; Hodgson, Lydia; Herndon 2nd, James E et al. (2009) Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer. J Thorac Oncol 4:1117-25
Katz, Mira L; Donohue, Kathleen A; Alfano, Catherine M et al. (2009) Cancer surveillance behaviors and psychosocial factors among long-term survivors of breast cancer. Cancer and Leukemia Group B 79804. Cancer 115:480-8
Alfano, Catherine M; Day, Jeannette M; Katz, Mira L et al. (2009) Exercise and dietary change after diagnosis and cancer-related symptoms in long-term survivors of breast cancer: CALGB 79804. Psychooncology 18:128-33
Blanke, Charles D; Rankin, Cathryn; Demetri, George D et al. (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626-32
Bogart, Jeffrey A; Watson, Dorothy; McClay, Edward F et al. (2008) Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: analysis of CALGB phase III trial 9235. Lung Cancer 62:92-8

Showing the most recent 10 out of 53 publications